Nextpoint Therapeutics, Inc.

CAMBRIDGE, Mass.--( BUSINESS WIRE )-- NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39 th Annual Meeting, being held from November 6-10, 2024 in Houston, Texas. Building on its deep biological understanding of the B7-H7 axis, NextPoint has developed a series of B7-H7 targeted bispecific CD3 engaging antibodies (BsAbs). These BsAbs are designed to bind both B7-H7 expressed on the surface of tumors cells and CD3 on the surface of T cells to induce potent T cell-mediated cytotoxicity toward B7-H7+ tumors independent of existing ADC/IO approaches. NextPoint’s B7-H7xCD3 BsAb 2:1 bispecific antibody design provides optimized target:CD3 affinity ratio, inactivated Fc effector function and ability to fully evaluate safety preclinically. Due to very limited normal tissue expression, B7-H7xCD3 is safe to administer in a wide dose range. Efficacy data presented at SITC demonstrates potent T cell-mediated cytotoxicity against multiple B7-H7+ tumor cell lines with sub-nanomolar EC50s in addition to induction of complete regressions in most of B7-H7+ tumor bearing mice. “Targeting B7-H7, a novel tumor antigen highly upregulated in cancer cells with restricted normal tissue expression profile, is a new frontier in the treatment of solid tumors. B7-H7 directed T cell engagers have the potential to overcome the complex tumor microenvironment and drive durable anti-tumor responses,” said Tatiana Novobrantseva, PhD, Chief Scientific Officer of NextPoint Therapeutics. "NextPoint’s T cell engagers’ precise activation of T cells in the proximity of B7-H7-positive cells combined with its potent anti-tumor activity in both in vitro and in vivo studies support our vision of developing effective and targeted B7-H7 immunotherapies. Complete regressions in vivo across multiple animal models is an impressive sign of efficacy showing that B7-H7 targeting BsAbs will push the boundaries of cancer treatments and become a powerful tool in our arsenal against a new group of B7-H7 biomarker defined patients with solid malignancies. Armed with tolerability data, NextPoint is rapidly advancing the Investigational New Drug (IND) application for our T cell engager, NPX372. We look forward to advancing this innovative approach into clinical development supported by the B7-H7 biomarker assay to enrich for responders.” Presentation Details: Title: B7-H7-CD3 Bispecific T cell Engaging Antibodies Demonstrate Potent Anti-Tumor Activity In B7-H7+ Preclinical Tumor Models Abstract Number: 1318 Date & Time: Saturday, November 9, 2024, 9:00 a.m.-7:00 p.m. CST Presenters: Matthew Rausch PhD, Director, Molecular Biology R&D, Karishma Vekaria, Research Associate, R&D Location: Exhibit Halls A B About NextPoint Therapeutics NextPoint is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed therapy, so that we can deliver a new class of monotherapies for patients. Our team of proven drug developers is simultaneously advancing therapeutic approaches blocking the B7-H7 immune signaling pathway and utilizing the unique upregulation of B7-H7 in cancer as an anchor for tumor-targeting treatment modalities. To learn more, visit nextpointtx.com .

CD3 bispecific antibody developed to redirect T cell-mediated immunity toward B7-H7 expressing tumors, expanding monotherapy treatment possibility for a new patient population Company’s precision immunotherapy approach enables prospective identification of patients most likely to benefit from NPX372 with a defined clinical biomarker CAMBRIDGE, MA, USA I September 05, 2024 I NextPoint Therapeutics , a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today has unveiled NPX372, a novel T cell engager. NPX372 further expands NextPoint’s multi-modal focus on the emerging B7-H7 axis in cancer therapy. B7-H7, also known as HHLA2, is an emerging immunomodulatory receptor upregulated in various solid tumor types, including colorectal carcinoma, non-small cell lung cancer, renal cell carcinoma, prostate cancer, and many others. Notably, this receptor is induced independently of PD-L1 or other B7 family members. Unlike other B7 family proteins that are expressed across a wide range of cell types, B7-H7 is primarily found on the epithelial cells of tumors, making it a unique and potentially specific target for tumor-directed therapies. “T cell engagers have shown immense potential, but to date their application in solid tumors has remained a formidable challenge. NPX372 represents a significant advancement, aiming to redirect T cell-mediated immunity with high specificity by modulating key biological components, potentially offering more effective monotherapy treatment options for a range of solid tumors,” said Tatiana Novobrantseva, PhD, Chief Scientific Officer of NextPoint Therapeutics. NPX372 is a CD3 bispecific antibody with unique capabilities to redirect T cell-mediated cytotoxicity toward B7-H7-positive tumors. In addition to CD3 engagement, this antibody interacts with the B7-H7 immune axis to achieve added potency. Preclinical data highlight NPX372’s potent anti-tumor responses and a favorable safety profile at clinically relevant doses with no indication of cytokine release syndrome. This asset is part of NextPoint’s diverse portfolio of immunotherapies designed to target various tumor types. NextPoint is rapidly advancing the Investigational New Drug (IND) application for NPX372. “NPX372 represents a significant advancement in our pursuit of precision immunotherapy,” said Ivan Cheung, CEO of NextPoint Therapeutics. “As part of our ongoing immune checkpoint clinical programs, NPX267 and NPX887, we have developed a clinical biomarker for B7-H7 expression, which allows us to selectively target patients across various tumor types who may benefit from a potent T cell engager such as NPX372. This precision medicine approach allows us to potentially address solid tumors expressing B7-H7, tailoring treatments to those who will respond best. Our deep knowledge of B7-H7 biology drives our leadership in advancing innovative, transformative treatments that can make a meaningful difference in the lives of cancer patients.” About NextPoint Therapeutics NextPoint is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed therapy, so that we can deliver a new class of monotherapies for patients. Our team of proven drug developers is simultaneously advancing therapeutic approaches blocking the B7-H7 immune signaling pathway and utilizing the unique upregulation of B7-H7 in cancer as an anchor for tumor-targeting treatment modalities. To learn more, visit nextpointtx.com . SOURCE: NextPoint Therapeutics

NEW YORK, May 2, 2024 /PRNewswire/ -- Today, TIME reveals the inaugural TIME100 Health list recognizing the 100 most influential individuals in health.To assemble this list, TIME reporters and editors spent months consulting sources and experts around the world to select the 100 individuals who are most influential in the world of health right now. The result is the TIME100 Health, a community of leaders from across industries—scientists, doctors, advocates, educators and policy-makers, among others—dedicated to creating tangible, credible change for a healthier world. Continue Reading TIME100 Health cover featuring an illustration by Peter Greenwood for TIME --See the complete 2024 TIME100 Health list: time.com/time100health --See the TIME100 Health cover featuring an illustration by Peter Greenwood for TIME: TIME Editor-in-Chief Sam Jacobs writes in his letter to readers: "Together, the individuals on the TIME100 Health list are a reminder that many things are going right, and their work is enough to inspire the belief that the world of health is in the middle of a golden age of accomplishment and transformation…. Health innovation, like this list, reflects humanity at its best: people using all their resourcefulness and ingenuity to help one another live better…. Whether you are familiar with the individuals on this list or this is the first time you're reading about them, their work is changing the lives of people in your community and around the world." FROM THE 2024 TIME100 HEALTH LIST: The 2024 TIME100 Health list features CEOs, founders, and co-founders including: Lars Fruergaard Jørgensen of Novo Nordisk, Albert Bourla of Pfizer, Alex Oshmyansky of Mark Cuban Cost Plus Drug, Dave Ricks of Eli Lilly, Dima Gazda of Esper Bionics, Dora Chomiak of Razom, Bobby Gaspar of Orchard Therapeutics, Greg Adams of Kaiser Permanente, Ivan Cheung of NextPoint Therapeutics, Kim Nolte of Migrant Clinicians Network, Akiko Iwasaki of ImmunoACT, and more.Women featured on the list include: executive director of the NAAFA Tigress Osborn, chemist Svetlana Mojsov, VP of Health at Apple Sumbul Desai, educator Ruth Gottesman, instructor in the Department of Environmental Health Ronnie Levin, executive director of GIRE Rebeca Ramos, chief science officer at Salignostics Raluca Cohen, EVP of global operations, global IT and chief sustainability officer at AstraZeneca Pam Cheng.The youngest individual recognized on the inaugural TIME100 Health list is 28-year-old Dale Whelehan, CEO of Four Day Week Global. On the other end is 99-year-old Jimmy Carter, 39th U.S. President, for his decades-long fight to eradicate Guinea worm, which is nearing completion.The list also features creatives and entertainers including: actors Michael J. Fox, Halle Berry, and Olivia Munn, authors Alua Arthur and Peter Attia, and professor and author Jonathan Haidt.Scientists, doctors, and researchers recognized on the list include those focused on health innovation: cancer researcher Thomas Powles; research scientist Jenna Forsyth; chief science officer of National Wastewater Surveillance System Amy Kirby; GLP-1 discoverers Dan Drucker, Joel Habener, Svetlana Mojsov, and Jens Juul Holst; neurosurgeon Jocelyne Bloch and neuroscientist Gregoire Courtine; executive director of Palestinian Red Crescent Bashar Murad, professor and researcher Hadiza Shehu Galadanci, and more.Policy-makers and government officials on this year's list include: President of France Emmanuel Macron, CDC Director Mandy Cohen, administrator of the U.S. Environmental Protection Agency Michael Regan, Governor of Ohio Mike DeWine, Pennsylvania Senator John Fetterman, U.S. Surgeon General Vivek Murthy, administrator of Centers for Medicare and Medicaid Services Chiquita Brooks-LaSure, chief of Global Drug Facility Brenda Waning, and more. See the full 2024 TIME100 Health list here: time.com/time100health TIME will convene the TIME100 Impact Dinner: Leaders Shaping the Future of Health to spotlight an array of leaders including those featured on the new TIME100 Health list of 100 individuals on May 13th in New York City. The event will feature conversations focused on driving innovation and setting trends within the healthcare sector with appearances by actor, filmmaker and entrepreneur Halle Berry, medical scientist Marlena Fejzo, global health expert Alaa Murabit, founder and director of the Scripps Research Translational Institute Eric Topol and more.The TIME100 Impact Dinner: Leaders Shaping the Future of Health is presented by premier partner Eli Lilly and Company, signature partner Northwell Health and supporting partner On Purpose, A Podcast by Jay Shetty. Contact: Emily Alwell, TIME [email protected] About TIME TIME is the 101-year-old global media brand that reaches a combined audience of over 120 million around the world through its iconic magazine and digital platforms. With unparalleled access to the world's most influential people, the trust of consumers and partners globally, and an unrivaled power to convene, TIME's mission is to tell the essential stories of the people and ideas that shape and improve the world. Today, TIME also includes the Emmy Award®-winning film and television division TIME Studios; a significantly expanded live events business built on the powerful TIME100 and Person of the Year franchises and custom experiences; TIME for Kids, which provides trusted news with a focus on news literacy for kids and valuable resources for teachers and families; the award-winning branded content studio Red Border Studios; the website-building platform TIME Sites; the sustainability and climate action division TIME CO2; the new e-commerce and content platform TIME Stamped, and more. SOURCE TIME